Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities

Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

(2023) Joe-Elie Salem et al.   Cancer Discovery

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

(2022) Inês Pires da Silva et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-checkpoint inhibitors: long-term implications of toxicity

(2022) Douglas B. Johnson et al.   Nature Reviews Clinical Oncology

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer

(2022) Ruibin Yi et al.   Frontiers in Cell and Developmental Biology

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

(2022) Rebecca C. Simpson et al.   NATURE MEDICINE

The association between tumor mutational burden and prognosis is dependent on treatment context

(2021) Cristina Valero et al.   NATURE GENETICS

Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

(2021) Cristina Valero et al.   JAMA Oncology

Endocrine toxicities of immune checkpoint inhibitors

(2021) Jordan J. Wright et al.   Nature Reviews Endocrinology

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

(2021) J. Randall Patrinely et al.   JAMA Oncology

Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy

(2021) Xue Bai et al.   CLINICAL CANCER RESEARCH

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

(2021) Paula I. Gonzalez-Ericsson et al.   CLINICAL CANCER RESEARCH

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

(2021) F. Stephen Hodi et al.   Cancer Immunology Research

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

(2021) Jedd D. Wolchok et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

(2020) Daixi Ren et al.   Molecular Cancer

Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency

(2020) Seiichi Yano et al.   EUROPEAN JOURNAL OF CANCER

Overcoming genetically-based resistance mechanisms to PD-1 blockade

(2020) Davis Y. Torrejon et al.   Cancer Discovery

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

(2020) Catherine S. Grasso et al.   CANCER CELL

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention

(2020) Spencer C Wei et al.   Cancer Discovery

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study

(2020) Meredith S. Pelster et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

(2019) Yosuke Togashi et al.   Nature Reviews Clinical Oncology

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

(2019) Douglas B. Johnson et al.   NATURE MEDICINE

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

(2019) Joe-Elie Salem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

(2019) Steve Lu et al.   JAMA Oncology

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors

(2019) Sadal Refae et al.   INVESTIGATIONAL NEW DRUGS

C-reactive protein as an early marker of immune-related adverse events

(2019) Amir-Reza Abolhassani et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis

(2019) Yoshito Zamami et al.   JAMA Oncology

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

(2018) Alexander T. Faje et al.   CANCER

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma

(2018) Douglas B. Johnson et al.   CLINICAL CANCER RESEARCH

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab

(2018) Richard W. Joseph et al.   CLINICAL CANCER RESEARCH

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

(2018) Angeliki M. Stamatouli et al.   DIABETES

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

(2018) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

(2018) Sara Valpione et al.   Journal of Translational Medicine

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

(2018) Scott J. Rodig et al.   Science Translational Medicine

Association of anti-thyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

(2018) Shiro Kimbara et al.   CANCER SCIENCE

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts

(2018) Jonathan E. Wosen et al.   Frontiers in Immunology

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer

(2018) Margaret L Axelrod et al.   CLINICAL CANCER RESEARCH

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

(2018) Douglas B. Johnson et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Inhibitor Toxicity in 2018

(2018) Douglas B. Johnson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Emerging biomarkers for cancer immunotherapy in melanoma

(2017) Margaret L. Axelrod et al.   SEMINARS IN CANCER BIOLOGY

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

(2016) Alexander N. Shoushtari et al.   CANCER

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

(2016) Alain P. Algazi et al.   CANCER

Rejection versus escape: the tumor MHC dilemma

(2016) Federico Garrido et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

(2016) Bridgette A. Kanz et al.   Journal for ImmunoTherapy of Cancer

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Opportunistic infections in patients treated with immunotherapy for cancer

(2014) Chrisann Kyi et al.   Journal for ImmunoTherapy of Cancer

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

T Cells at the Site of Autoimmune Inflammation Show Increased Potential for Trogocytosis

(2013) Bettina Haastert et al.   PLoS One

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

(2012) P. A. Prieto et al.   CLINICAL CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes

(2010) R. Bos et al.   CANCER RESEARCH

“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy

(2010) Federico Garrido et al.   INTERNATIONAL JOURNAL OF CANCER

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

(2008) Jessica B. Katz et al.   IMMUNOLOGICAL REVIEWS